Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. Reply.
| Autor: | Egbuna O; Vertex Pharmaceuticals, Boston, MA ogo_egbuna@vrtx.com., Chertow GM; Stanford University School of Medicine, Palo Alto, CA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The New England journal of medicine [N Engl J Med] 2023 Jun 29; Vol. 388 (26), pp. 2491. |
| DOI: | 10.1056/NEJMc2304780 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|